Issuance of the seventh tranche of 40 bonds convertible into shares
AMOEBA announces the issuance of the seventh tranche of 40 bonds convertible into shares
Chassieu (France), December 14, 2022– 5.45 pm – AMOEBA (FR0011051598 – ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, still in a development phase, announces the issuance of the seventh tranche of bonds convertible into shares (“OCAs”) of its bond financing with incentive program, namely 40 OCAs numbered from 361 to 400 fully issued to Nice & Green S.A.
This issue is part of the agreement entered into with Nice & Green S.A. on December 16, 2020 with a view to setting up a bond financing with a profit-sharing program through the issuance of 480 OCAs with a nominal value of EUR 50,000 each, representing a total nominal amount of the bond issue of EUR 24,000,000 (the “Issuance Agreement”).1
The Chairman and Chief Executive Officer of the Company, using the sub-delegation granted to him by the Board of Directors at its meeting on June 24, 2021, decided to issue on December 13, 2022, 40 OCAs numbered from 361 to 400 to the benefit of Nice & Green S.A. corresponding to the seventh tranche of the bond financing.
As provided for in the issuance agreement, these OCAs were fully subscribed at a price equal to 96% of their nominal value, representing a seventh tranche of OCAs for a total net amount of EUR 1,920,000.
As a reminder, the Company maintains on its website a monitoring table of the OCAs and the number of Amoéba shares in circulation (see Investors section / Regulatories information / Other information).
As an indication, the theoretical impact of the issue of this seventh tranche of OCAs is presented in the tables below in accordance with the OCA conversion formulas on the basis of 92% of the lowest volume-weighted average trading price of the Amoéba share at closing (as published by Bloomberg) over the six (6) trading days immediately preceding December 13, 2022, namely 0.8238 euros.
– Impact of the issue on the share of shareholders’ equity per share (calculation based on Amoéba’s shareholders’ equity as at june 30, 2022, prepared in accordance with International Financial Reporting Standards (IFRS) adjusted for capital increases completed up to December 13, 2022 i. e. 10,572,011 euros and the number of shares comprising the Company’s share capital as at December 13, 2022, i. e. 46,309,880 shares) :
(*) amount of shareholders’ equity at 30 june 2022 prepared in accordance with IFRS international financial standards and adjusted for capital increases completed until December 13, 2022
(**) assuming the full exercise of the share subscription warrants issued and allocated by Amoéba, exercisable or not, giving the right to subscribe for 200,000 new shares
– Impact of the issue on the participation of a shareholder holding 1% of Amoéba’s share capital prior to the issue of the seventh tranche (calculation based on the number of shares comprising Amoéba’s share capital as at December 13, 2022, i.e. 46,309,880 shares) :
(*) assuming the full exercise of the share subscription warrants issued and allocated by Amoéba, exercisable or not, giving the right to subscribe for 200,000 new shares